Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 07 May 2019

At a glance

  • Drugs Dupilumab (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 07 May 2019 According to a Regeneron Pharmaceuticals media release, based on the clinical data (n=2888) from three trials (global LIBERTY ASTHMA program (QUEST, VENTURE, phase 2b-DRI12544), the European Commission has approved Dupixent for use in adults and adolescents 12 years and older as an add-on maintenance treatment for severe asthma with type 2 inflammation.
    • 01 Mar 2019 According to a Sanofi media release, based on the clinical data (n=2888) from three pivotal trials of the global LIBERTY ASTHMA program (QUEST, VENTURE, phase 2b-DRI12544), the European Medicines Agency's CHMP has adopted a positive opinion for Dupixent (dupilumab) and recommended its approval in the EU for use in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation.
    • 19 Oct 2018 According to a Sanofi media release, based on the results of LIBERTY ASTHMA VENTURE, Liberty Asthma Quest and DRI12544, the U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment in certain adults and adolescents (12 years of age and older) with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top